Fig. 3: A genome-wide CRISPR/Cas9 screen identifies genetic dependencies of melanoma cells with high YAP1 activity.
From: Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors
a Experimental layout of genome-wide screen for genetic dependencies of SKMEL28-YAP5SA melanoma cells ± Vemurafenib (Vem) treatment and EV control cells (the experiment was performed with three replicates per cell line). b Change in sgRNA abundance (end of the experiment compared to start) per gene comparing SKMEL28-YAP5SA cells without treatment and SKMEL28-EV cells (blue labels indicate expected hits; fc, fold change). c Change in sgRNA abundance per gene comparing SKMEL28-YAP5SA cells treated with or without 5 µM Vemurafenib (blue labels indicate expected hits; green labels indicate hits selected for validation). d Strategy for selection of hits for validation focusing on genes whose sgRNAs were all only essential for Vemurafenib-treated SKMEL28-YAP5SA cells. e Change in sgRNA abundance for SLC35B2 in screened SKMEL28 cell lines (mean ± SD of three replicates is presented).
